The relationship between hepatocellular carcinoma and Resolvin D1

Aims: Liver cancer is the second most common cause of cancer death, and hepatocellular carcinoma (HCC) is the most common hepatic primary tumor. Hepatocellular carcinoma develops based on inflammation in the cirrhotic liver. The aim of our study was to determine the relationship between the decrease in Resolvin D1, the lipid mediator involved in the resolution, and hepatocarcinogenesis. Methods: Thirty patients with HCC, thirty patients with cirrhosis, and thirty healthy subjects followed in our clinic between March 2018 and June 2019 were included in the study. Routine laboratory test results of the patients were recorded from the institutional database. Resolvin D1 and other parameters of the study groups were compared. Results: The Resolvin D1 levels were found to be significantly different from each other group, with the ranking as follows: the HCC group (1.71 ± 1.46 ng/ml)< the cirrhotic group (3.63 ± 2.92 ng/ml)< the healthy control group (6.24 ± 3.18 ng/ml). Moreover, Resolvin D1 levels were negatively correlated with ?-fetoprotein (AFP) level and tumor stage. Conclusion: Reduced lipid mediators that aid in the resolution process cause an increase in pro-inflammatory cytokines involved in the development of hepatocellular carcinoma. A decrease in Resolvin D1 may serve as a biomarker contributing to the diagnosis of progression to HCC in cirrhotic patients by triggering chronic inflammation and hepatocarcinogenesis.